UMBRALISIB TOSYLATE | TG THERAPS | ||
EQ 200MG BASE | |||
No | No | ||
2035-May-26 | 2026-Feb-05 | ||
None | None | ||
None | No | ||
UKONIQ is a kinase inhibitor indicated for the treatment of adult patients with: • Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen. • Relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy. |
0 | 0 | 0 |
Total Other Developers | None |
---|
Drugs with Suitability | No |
---|
EQ 200MG BASE | ** | ** | - | - | - |
NDA Sales Available | Total Generic Sales Available |
---|---|
Yes | 0 |
ANDA No | Generic Co | Manufacturer Name | Operations | Manufacturer Address | Country |
---|
Download GenUS Drug Report
Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023
+91 94997 68112
nimish@researchdelta.com